

NeuTec Pharma plc

NeuTec signs Manufacturing Partner for Mycograb®

29 November 2004 - Manchester, UK: *NeuTec* Pharma plc ("*NeuTec*" or the "Company"), the biopharmaceutical company targeting drug-resistant, life-threatening infections, announces that it has signed a contract for the commercial scale manufacturing of Mycograb®, the Company's lead product targeting invasive candidiasis.

Following an extensive review of Contract Manufacturing Organisations ("CMO"s), *NeuTec* has today secured a second manufacturer of Mycograb® to provide large-scale drug supplies in anticipation of eventual market launch. The contract with CMC Biopharmaceuticals ("CMC"), a Danish based CMO specialising in *E. coli* fermentation, will provide *NeuTec* with development, manufacturing, analytical and quality control services. The technology transfer process has now commenced.

Prof. James Burnie, Chief Executive Officer of *NeuTec*, commented:

"We are progressing with Mycograb® on schedule. We have raised the money needed to commercialise the product and appointed a head of commercial development. We are now delighted to be able to announce the appointment of a second commercial scale contract manufacturer to consolidate our position as we move towards the commercialisation of the product."

For further details please contact:

NeuTec Pharma plc

Professor James Burnie, CEO

Andrew King, Finance Director

www.neutecpharma.com

0161 276 8827

07771 867890

Financial Dynamics

Deborah Scott / Ben Atwell

0207 831 3113